Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals' stock has experienced significant events in the past six months. The stock rose by 242% over the past year due to clinical pipeline developments. In November 2025, the company completed a public offering, raising $218.5 million, increasing its cash position to $505.4 million by year-end 2025. In March 2026, Olema reported its Fourth Quarter and Full Year 2025 financial results, outlining key upcoming catalysts. The company also presented positive preclinical data at the AACR Annual Meeting in April 2026. However, the stock dropped 41% in March 2026 following Roche's negative Phase 3 trial results, raising concerns about oral SERDs. Analysts reduced price targets, and a shelf registration filing raised dilution concerns. Insider selling of approximately $23.0 million also occurred.

Olema Pharmaceuticals, Inc. does not exhibit traditional demand seasonality for its products or services, as its primary activities revolve around research, development, and clinical trials rather than commercial product sales.

Olema Pharmaceuticals, Inc. is dedicated to discovering, developing, and commercializing targeted therapies for women's cancers, particularly breast cancer. The company's lead product candidate, palazestrant (OP-1250), is in Phase 3 clinical trials for recurrent, locally advanced, or metastatic ER-positive, HER2-negative breast cancer. Olema is also developing OP-3136, an orally available small molecule that inhibits KAT6, currently in Phase 1 clinical trials for breast and other solid tumor cancers.

Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, and maintains operations in Cambridge, Massachusetts.

Olema Pharmaceuticals generally has a positive brand reputation, particularly regarding its clinical pipeline. Analyst consensus is a "Moderate Buy," with some analysts issuing "Strong Buy" ratings. The company's advancements in its clinical pipeline, especially palazestrant, have driven this positive sentiment. However, the failure of Roche's Phase 3 trial in March 2026 led to a stock drop and raised concerns about oral SERDs. A shelf registration filing raised questions about potential dilution, and significant insider selling also affected investor perception. Despite these challenges, the company's strong cash position and ongoing clinical advancements continue to underpin analyst confidence.

Olema Pharmaceuticals, Inc. is primarily owned by institutional shareholders, who hold 104.10% of the stock, while insiders own 29.02%, and retail investors hold 0.00%. As of April 9, 2026, there were 205 institutional owners holding 90,480,847 shares. Major institutional owners include Bain Capital Life Sciences Investors, LLC, Paradigm Biocapital Advisors LP, Janus Henderson Group Plc, BlackRock, Inc., BVF Inc/il, Fmr Llc, Vanguard Group Inc, Siren, L.L.C., Logos Global Management LP, and Cormorant Asset Management, LP. Bain Capital Life Sciences Investors LLC is the largest individual shareholder, owning 8.61% of the company's shares.